Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
As Medicare announced a fresh set of drugs selected for its price-setting process on Friday under the Inflation Reduction Act ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
Newer entrants to the pharmacy benefit management market will continue to face stiff competition in 2025 as they seek more ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback